Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy
Open Access
- 23 April 2025
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 32 (5) , 1-8
Abstract
Supported by encouraging trial outcomes, onasemnogene abeparvovec (OA) was authorized for spinal muscular atrophy (SMA). Nevertheless, efficacy of OA in advanced SMA patients remains underexplored. This investigation assessed clinical effectiveness and adverse effects of OA in a cohort including advanced SMA, and compared to historical survival data for SMA type 1 patients in Thailand. We conducted observational cohort study at Siriraj Hospital, Thailand, from May 2019 to April 2022. The study enrolled eight SMA patients receiving OA therapy. The cohort comprised five SMA type 1 patients treated at 16.7 months (6.5–24.9 months) and three SMA type 2 patients treated at 20.3 months (19–31.5 months). Before receiving OA, all Type 1 patients required 24-hour invasive ventilation and feeding support. Post-treatment, Three of five showed gradual improvement in motor scores, but none achieved new motor milestones. Survival rate was not improved, with all experiencing fatalities. Conversely, Type 2 patients exhibited motor score improvement without serious adverse events. OA did not significantly improve clinical outcomes or survival rates in advanced Type 1 SMA. These findings highlight need for additional caution when administering OA to severe SMA Type 1 and more specific guidelines in selecting subgroups for treatment.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- 2024 update: European consensus statement on gene therapy for spinal muscular atrophyEuropean Journal of Paediatric Neurology, 2024
- Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access ProgramPediatric Neurology, 2022
- Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacyAnnals of Clinical and Translational Neurology, 2022
- Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec TherapyDrug Safety, 2021
- Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular AtrophyPediatric Neurology, 2021
- Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophyJournal of Hepatology, 2021
- Onasemnogene Abeparvovec: First Global ApprovalDrugs, 2019
- SMA THERAPIES II AND BIOMARKERSNeuromuscular Disorders, 2018
- Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethicsNeuromuscular Disorders, 2018
- Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional careNeuromuscular Disorders, 2018